The REG1 Anticoagulation System

By John P. Vavalle, MD

The RADAR trial examined the safety and efficacy of the novel REG1 anticoagulation system, as compared to heparin, in patients with acute coronary syndrome being treated with an invasive approach.  The REG1 anticoagulation system is comprised of a novel, aptamer-based factor IXa inhibitor (pegnivacogin) and its Watson-Crick base-pair antidote (anivamersen).  This system allows for very rapid high-level anticoagulation that is titratable or even completely reversible within minutes depending on the dosing of the antidote.  RADAR demonstrated that at least 50% reversal is needed for safe sheath removal from the femoral artery.

Our study sought to examine the differences in femoral arterial sheath management between the REG1 and heparin arms, and to explore whether REG1 could allow for very early safe sheath removal without an increase in vascular-access complications.  Indeed, this study demonstrated that those randomized to REG1, as opposed to heparin, had much shorter times to sheath removal (26 min [18, 46]) vs. (210 min [102, 342]) without an increase in the median time to hemostasis, increased rates of vascular-access bleeding complications, or time to ambulation.  Further studies are needed to determine if the shorter times to removal of the arterial sheath will lead to reductions in hospital length of stays or reduced costs in patients being treated invasively for acute coronary syndrome.  

A selection of articles on Anticoagulation and Arterial Sheath Removal:

This entry was posted in Uncategorized and tagged , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s